REGULATORY UPDATE: CBER Announces 2024 Science Symposium

The Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER) recently released the program agenda for its 2024 Science Symposium, taking place Sept. 16-18 in a hybrid format. Registration is open to the public.

The symposium will explore topics related to the regulation of biologics and highlight science conducted at CBER by showcasing how scientific research informs regulatory decision-making. It will also provide a forum for developing collaborations within FDA and with external organizations.

Expert-led presentations at the symposium will address emerging and re-emerging diseases; advanced manufacturing and analytics, including new and emerging technologies; immune response to vaccination; methods and biomarker discovery for product safety and quality; advances in computational science supporting biologics’ evaluation; and cell, tissue and gene therapy.